Yuri A. Piven¹, Danila V. Sorokin², Nastassia A. Varabyeva¹, Alexandra L. Mikhaylova², Fedor B. Bogdanov², Elena V. Shafranovskaya¹, Raman M. Puzanau³, Fedor A. Lakhvich¹, Alexander M. Scherbakov^2,4,*

Oncology Research, Vol.33, No.12, pp. 4049-4072, 2025, DOI:10.32604/or.2025.067832 - 27 November 2025

Abstract Background: The most aggressive forms of breast cancer are characterized by independence from steroid hormones but a strong dependence on growth factors. In such cancer cells, oncogenic receptors, including human epidermal growth factor receptor 2 (HER2), are activated, and their targeted inhibition represents an attractive therapeutic strategy. The study aimed to develop small-molecule potential dual heat shock protein 90 (HSP90)-HER2 inhibitors and evaluate them as anticancer agents in HER2-positive cells. Methods: The research project involved obtaining a series of compounds with potential dual inhibitory activity against HSP90 and HER2 by targeted organic synthesis, which was… More > Graphic Abstract

Eleni Kokkotou^*, Andriani Charpidou, Nikolaos Syrigos

Oncology Research, Vol.33, No.10, pp. 2657-2672, 2025, DOI:10.32604/or.2025.066228 - 26 September 2025

Abstract Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) serve an essential role in tumor angiogenesis and have emerged as potential therapeutic targets in lung cancer. This review explores the significance of serum VEGF levels as a predictive biomarker in non-small cell lung cancer (NSCLC). The VEGF family, consisting of VEGFA, VEGFB, VEGFC, VEGFD, and placenta growth factor (PlGF), engages with specific receptors, including tyrosine kinase receptors (VEGFR-1, VEGFR-2, and VEGFR-3) and neuropilin receptors (NRP-1 and NRP-2), to promote angiogenesis and lymphangiogenesis. VEGF-A, the primary component of the VEGF family, binds to VEGFR-2 to stimulate… More >

Xi Qin^1,#, Yulan Liu^1,#, Lin Zhu², Yunyan Mo¹, Jing Zhang³, Zhuchun Jiang⁴, Dongning Huang⁵, Xinrong Hu⁶, Jingzhang Li⁷, Quanfang Chen⁸, Feng Xue^1,*

Oncology Research, Vol.33, No.9, pp. 2451-2462, 2025, DOI:10.32604/or.2025.064119 - 28 August 2025

Abstract Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases. Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint. Adverse events… More >

KHANH TOAN NGUYEN^*, THI HUONG PHAM, VAN LAM NGO, VAN TUAN BUI, VAN NHAT NGUYEN, THI PHUONG THAO NGUYEN, THI KHANH HA NGUYEN, THI THUY VAN NGUYEN

Oncology Research, Vol.33, No.7, pp. 1667-1677, 2025, DOI:10.32604/or.2025.061905 - 26 June 2025

Abstract Aims: The study aimed to evaluate the effectiveness and adverse events of tyrosine kinase inhibitors (TKIs) in the first-line treatment of advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Methods: A retrospective study on advanced NSCLC patients with EGFR mutations treated with TKIs as a first-line therapy at Nghe An Oncology Hospital, Vietnam between January 2017 and August 2023. The primary endpoints included objective response rate, progression-free survival, and tolerability. The secondary endpoint was overall survival. Results: A total of 211 patients received first-line treatment with Erlotinib (n = 74), Gefitinib (n… More >

DEXUE FAN^1,#, WEI SU^2,#, ZHAOWEN BI³, XINXING WANG¹, XIANWEN XU¹, MINGZE MA⁴, LICHAO ZHU⁵, ZHENHAI ZHANG^1,3,*, JUNLIN GAO^2,*

Oncology Research, Vol.33, No.6, pp. 1459-1472, 2025, DOI:10.32604/or.2025.060407 - 29 May 2025

Abstract Objectives: Apatinib has been reported to be a promising treatment for sorafenib-resistant hepatocellular carcinoma (HCC) patients. However, the underlying mechanism remains ambiguous. The study aimed to explore the efficacy of apatinib in sorafenib-resistant HCC and the underlying mechanism both in vitro and in vivo. Methods: After observing epithelial-mesenchymal transformation (EMT) changes in HepG2 and HepG2/Sorafenib cells, we treated them with varying concentrations of apatinib to assess its impact on sorafenib-resistant HCC. Subsequently, specific inhibitors of c-Jun N-terminal kinase (JNK, SP600125) and extracellular signal-regulated kinase (ERK, PD98059) were introduced to investigate whether apatinib influenced sorafenib-resistant HCC via modulation… More >

YUZHENG LI^1,2, LILI YU¹, SHIYAO ZHOU¹, HUA ZHOU^2,3,*, QIBIAO WU^1,2,*

Oncology Research, Vol.33, No.6, pp. 1363-1376, 2025, DOI:10.32604/or.2025.059311 - 29 May 2025

Abstract Background: Non-small cell lung cancer (NSCLC) involves complex alterations in the epidermal growth factor receptor (EGFR) signaling pathway. This study aims to integrate multimodal omics analyses to evaluate and enhance EGFR-targeted therapies. Methods: We reviewed and synthesized omics data—including genomics, transcriptomics, proteomics, epigenomics, and metabolomics data—related to the EGFR pathway in NSCLC, examined the clinical outcomes of current therapies and proposed new treatment strategies. Results: Integrated omics analyses revealed the multifaceted role of EGFR in NSCLC. Transcriptomic analysis revealed gene expression alterations due to EGFR mutations, with upregulation of oncogenes and downregulation of tumor suppressors. Proteomics More >

LUIZ FERNANDO LOPES SILVA^1,#, JULIETE NATHALI SCHOLL^1,#, AUGUSTO FERREIRA WEBER¹, CAMILA KEHL DIAS¹, PAULINE RAFAELA PIZZATO², VINíCIUS PIERDONá LIMA¹, JEAN SÉVIGNY^3,4, ANA MARIA OLIVEIRA BATTASTINI¹, FABRÍCIO FIGUEIRÓ^1,2,*

Oncology Research, Vol.33, No.4, pp. 951-964, 2025, DOI:10.32604/or.2024.055508 - 19 March 2025

Abstract Objectives: Glioblastoma (GB) is a grade IV glial tumor characterized by high malignancy and dismal prognosis, primarily due to high recurrence rates and therapeutic resistance. The epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK), regulates signaling pathways, including cell growth, proliferation, survival, migration, and cell death. Many cancers utilize immune checkpoints (ICs) to attenuate immune responses. CD73 is an enzyme that functions as an IC by hydrolyzing AMP to adenosine, suppressing immune cells in the tumor microenvironment. However, the role of CD73 in resistance to EGFR inhibitors is poorly understood. This study aims… More >

JIYUN PANG^1,2,#, WEIGANG XIU^1,#, YUEYUN CHEN⁴, WENJING LIAO^1,2, QIN ZHANG^3,*, HUASHAN SHI^4,*

Oncology Research, Vol.33, No.4, pp. 895-904, 2025, DOI:10.32604/or.2024.053363 - 19 March 2025

Abstract Background: Non-small cell lung cancer (NSCLC) is often accompanied by brain metastasis (BM), and the prognosis of patients with BM is poor. This study assesses the prognostic impact of BM in NSCLC patients with epidermal growth factor receptor (EGFR) mutations. Methods: We retrospectively evaluated 692 advanced NSCLC patients with EGFR mutations treated with tyrosine kinase inhibitors (TKIs) at West China Hospital from 2015 to 2019. The overall survival rate (OS), progression-free survival rate (PFS), objective response rate (ORR), disease control rate (DCR), and clinical parameters of the BM and non-BM groups were compared. Univariable and multivariable… More >

QI LV^1,#, GANGMIN WANG^2,#, YI HONG¹, TIANYI ZHU¹, SHUANG QIN¹, SAIFEI SUN¹, YUTING WANG¹, YAOHUA LIU¹, QING ZHANG¹, CHUNHUI MA^3,*, PEIJUN WANG^1,*

Oncology Research, Vol.33, No.2, pp. 407-420, 2025, DOI:10.32604/or.2024.047698 - 16 January 2025

Abstract Background: Sunitinib resistance is a major challenge in advanced renal cell carcinoma (RCC). Clinically, elucidating the underlying mechanisms and developing practical countermeasures for sunitinib resistance in RCC is desirable. In previous studies, we found that circAGAP1 expression was significantly upregulated in clear cell RCC (ccRCC) and was strongly associated with poor prognosis. However, the role of circAGAP1 in sunitinib resistance in ccRCC remains unclear. Methods: We used public databases for bioinformatics analysis to identify the binding targets of circAGAP1. Additionally, the effects of circAGAP1 on the proliferation, clonogenesis, apoptosis, and migration of ccRCC cells were… More > Graphic Abstract

Xunguang Yan^1,2, Wenrui Wang¹, Fanglin Lu¹, Hongyong Fan³, Bo Wu¹, Jianfeng Yu^1,*

CMC-Computers, Materials & Continua, Vol.82, No.1, pp. 1439-1458, 2025, DOI:10.32604/cmc.2024.057797 - 03 January 2025

Abstract To maintain the reliability of power systems, routine inspections using drones equipped with advanced object detection algorithms are essential for preempting power-related issues. The increasing resolution of drone-captured images has posed a challenge for traditional target detection methods, especially in identifying small objects in high-resolution images. This study presents an enhanced object detection algorithm based on the Faster Region-based Convolutional Neural Network (Faster R-CNN) framework, specifically tailored for detecting small-scale electrical components like insulators, shock hammers, and screws in transmission line. The algorithm features an improved backbone network for Faster R-CNN, which significantly boosts the More >